Call for papers in the Journal of Venomous Animals and Toxins including Tropical Diseases.
Edited by Andre G. Tempone and Erika G. Pinto
Neglected tropical diseases (NTDs) are a diverse group of diseases mainly found in tropical and subtropical regions of 149 countries. It is estimated that over 1 billion people are infected with NTDs, with a further 1 billion at risk. Among them, diseases caused by protozoan parasites affect millions of people worldwide, mainly the poorest ones in developing countries. However, such infections have been largely neglected in drug research and development. Most of the current medicines used to treat these diseases are old and have many limitations, including the emergence of drug resistance.
Edited by Prof. Andre G. Tempone (Institute Adolfo Lutz of São Paulo, Brazil) and Dr. Erika G. Pinto (University of Dundee, Scotland), this thematic series aims to build bridges between novel hit or lead compounds and new alternative therapies for neglected protozoan diseases (including malaria). We welcome contributions describing the in vitro and/or in vivo activity of antiprotozoan compounds isolated from natural products (pure and well-characterized substances) and synthetic compounds. Additionally, we also welcome contributions using drug repurposing (or repositioning) approaches, based in approved drugs. The antiprotozoan compounds to be considered as new hit or lead compounds, must be based in strong drug discovery criteria, as: i) potency, ii) selectivity index (or therapeutic index), iii) elimination of interference compounds (pan-assay interference compounds – PAINS), and iv) lack of important structural alerts for known toxic compounds. Contributions describing the mechanism of action (MoA) of drugs, or other active compounds in protozoans are also welcome, using cellular, molecular and/or in silico approaches.
The proposed deadline for submissions is April 30, 2018. The editors invite you to share your knowledge on this exciting subject and submit your manuscript for consideration.
Manuscripts should be formatted according to our submission guidelines and submitted via the online submission system. In the submission system please make sure the correct collection title is chosen from the additional information tab. Please also indicate clearly in the covering letter that the manuscript is to be considered for the “Novel hit and lead compounds against neglected protozoan diseases” series.
If you would like to enquire about the suitability of a manuscript for consideration, please email a pre-submission enquiry to firstname.lastname@example.org.
Second-generation pterocarpanquinones: synthesis and antileishmanial activity
Despite the development of new therapies for leishmaniasis, among the 200 countries or territories reporting to the WHO, 87 were identified as endemic for Tegumentary Leishmaniasis and 75 as endemic for Viscer…
Efficacy of sertraline against Trypanosoma cruzi: an in vitro and in silico study
Drug repurposing has been an interesting and cost-effective approach, especially for neglected diseases, such as Chagas disease.
Activity of the antiarrhythmic drug amiodarone against Leishmania (L.) infantum: an in vitro and in vivo approach
Considering the high toxicity and limited therapies available for treating visceral leishmaniasis (VL), the drug repositioning approach represents a faster way to deliver new therapies to the market.
Neolignans isolated from twigs of Nectandra leucantha Ness & Mart (Lauraceae) displayed in vitro antileishmanial activity
The therapeutic arsenal for the treatment of Leishmaniasis is limited and includes toxic compounds (antimonials, amphotericin B, pentamidine and miltefosine). Given these aspects, the search for new compounds …
4-Phenyl-1,3-thiazole-2-amines as scaffolds for new antileishmanial agents
There is still a need for new alternatives in pharmacological therapy for neglected diseases, as the drugs available show high toxicity and parenteral administration. That is the case for the treatment of leis…
Impact of autologous whole blood administration upon experimental mouse models of acute Trypanosoma cruzi infection
Autologous whole blood (AWB) administration is described as alternative/complementary medical practice widely employed in medical and veterinary therapy against infections, chronic pathologies and neoplasias. …
Effect of phospholipase A2 inhibitors during infection caused by Leishmania (Leishmania) amazonensis
Lipid metabolites play an important role in parasite differentiation and virulence. Studies have revealed that Leishmania sp. uses prostaglandins to evade innate barriers, thus enabling the parasites to survive i…
Nanoparticulate drug delivery systems for the treatment of neglected tropical protozoan diseases
Neglected Tropical Diseases (NTDs) comprise of a group of seventeen infectious
conditions endemic in many developing countries. Among these diseases are three of
protozoan origin, namely leishmaniasis, Chagas disease, and African trypanosomiasis,
caused by the parasites Leishmania spp., Trypanosoma cruzi, and Trypanosoma brucei
Nitro-Heterocyclic compounds induce apoptosis-like effects in Leishmania (L.) amazonensis promastigotes
Three drugs – pentavalent antimonials, amphotericin B and pentamidine – are currently used for leishmaniasis treatment. They are administered for long periods, only parenterally, and have high cardiac, renal and hepatic toxicities. Therefore, the investigation of new compounds is required. Nitro-heterocyclic derivatives have been used as possible drug candidates to treat diseases caused by trypanosomatids.
Pharmacokinetics of neutron-irradiated meglumine antimoniate in Leishmania amazonensis-infected BALB/c mice
Cutaneous leishmaniasis (CL) is a parasitic disease caused by the protozoan Leishmania spp. Pentavalent antimonial agents have been used as an effective therapy, despite their side effects and resistant cases. Their pharmacokinetics remain largely unexplored. This study aimed to investigate the pharmacokinetic profile of meglumine antimoniate in a murine model of cutaneous leishmaniasis using a radiotracer approach.